Benitec Biopharma (BNTC) announces the appointment of Dr. Sharon Mates to the board of directors of the Company, effective November 2, 2025. Sharon Mates previously served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies from June 2002 until its acquisition
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTC:
- Benitec Biopharma’s BB-301 Study: A Potential Game-Changer for OPMD Treatment?
- Benitec Biopharma’s Strong Financial Position and Promising Clinical Progress Justify Buy Rating
- 3 Best Stocks to Buy Now, 9/24/2025, According to Top Analysts
- Benitec Biopharma Reports 2025 Financial Results and Progress
- Benitec Biopharma files $200M mixed securities shelf